 Connection
Christopher Porter to Antimetabolites, Antineoplastic
This is a "connection" page, showing publications Christopher Porter has written about Antimetabolites, Antineoplastic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.596 |
|
|
|
-
Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, Reigan P, Porter CC. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Mol Cancer Ther. 2013 Dec; 12(12):2675-84.
Score: 0.417
-
Porter CC, Kim J, Fosmire S, Gearheart CM, van Linden A, Baturin D, Zaberezhnyy V, Patel PR, Gao D, Tan AC, DeGregori J. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia. 2012 Jun; 26(6):1266-76.
Score: 0.092
-
Porter CC, Baturin D, Choudhary R, DeGregori J. Relative fitness of hematopoietic progenitors influences leukemia progression. Leukemia. 2011 May; 25(5):891-5.
Score: 0.087
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|